Trump diagnosed with vein condition causing leg swelling, White House says
Ms. Leavitt said there was "no evidence" of more serious conditions such as deep vein thrombosis or arterial disease. Additional exams identified "no signs of heart failure, renal impairment or systemic illness," Ms. Leavitt said.
Ms. Leavitt said Mr. Trump was not experiencing discomfort due to the condition.
According to the National Library of Health's MedlinePlus website, "Venous insufficiency is a condition in which the veins have problems sending blood from the legs back to the heart."
The condition "tends to get worse over time" but "can be managed if treatment is started in the early stated stages," the website says.
Ms. Leavitt also said that Mr. Trump had experienced bruising on the back of his hand.
She described this as "consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Donald Trump signs executive order to ‘Make America Fit Again': What is the Presidential Fitness Test as push-up tests return to schools
President Donald Trump has officially revived the iconic Presidential Fitness Test, once a hallmark of American physical education classes. With the stroke of an executive order on July 31, Trump aims to 'Make America Fit Again' by reinstating rigorous physical challenges for schoolchildren nationwide, including mile runs, push-ups, and sit-ups. Citing rising obesity rates and declining youth fitness, the Trump administration argues that performance-based assessments will foster a stronger, healthier generation. The move marks a sharp reversal of the Obama-era program that had shifted focus from physical performance to long-term wellness. Make America Fit Again : Trump's push to restore physical standards The Presidential Fitness Test was first introduced in 1956 by President Dwight Eisenhower to address concerns that American children were falling behind their global peers in physical health. It quickly became a staple in schools, assessing strength, endurance, and flexibility through standardized exercises. For decades, students trained to earn the coveted Presidential Fitness Award. But by 2013, the Obama administration replaced the test with a more holistic program focusing on lifelong health habits and personal fitness goals, marking a shift away from high-pressure physical benchmarks. Trump's executive order and new fitness goals Trump's latest executive order reintroduces the test across public schools and reinstates the President's Council on Sports, Fitness and Nutrition. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 20 Legendary Cars from the Past Undo Secretary of Health and Human Services Robert F. Kennedy Jr. has been tasked with overseeing the effort and shaping updated criteria for the modern era. The council will create new school-based programs, reward high-achieving students with a renewed Presidential Fitness Award, and help align the test with goals of American youth strength, military readiness, and healthy living. What the test includes for today's students The revived Presidential Fitness Test will include several familiar components that measure a student's physical capabilities: Push-ups for upper-body strength Sit-ups or crunches to test core endurance The sit-and-reach stretch for flexibility A one-mile run to evaluate cardiovascular stamina Pull-ups or the flexed-arm hang to assess muscular strength These tests will be evaluated against age-based benchmarks. While the test will be required in physical education classes, how results impact grading will vary by school district. Why the original test was removed in 2013 The Obama-era shift toward the Presidential Youth Fitness Program was designed to reduce competition and anxiety in fitness assessments. Health experts at the time argued the traditional test led to unhealthy comparisons, discouraged participation, and made students feel judged rather than supported. The new model emphasized personal progress and allowed teachers, students, and parents to use scores privately to encourage improvement rather than public performance. Pushback and concerns over Trump's mandate Despite strong support from Trump and his base, the return of the test has sparked pushback from educators and health professionals. Critics argue that: It may pressure students who struggle with physical activity Some schools lack the funding or staffing to properly implement it The focus on performance over progress could alienate children with physical challenges Nevertheless, the administration insists the rebooted test will include updated guidelines to promote fairness and student well-being while restoring national fitness goals. Fitness, patriotism, and politics Trump's revival of the test is about more than just exercise. 'Make America Fit Again' is both a slogan and a signal—a return to an era of discipline, competition, and national pride. The move aligns with his broader cultural message emphasizing strength, readiness, and traditional American values. As schools prepare to reintroduce this once-feared challenge, the question remains: will the old-school fitness test help shape a healthier generation, or reignite an old debate about how we define wellness in America's youth?
The Hindu
an hour ago
- The Hindu
U.S. President Donald Trump calls out Indian American Vasant Narasimhan, other big pharma CEOs to cut drug prices
In a rare and direct move, U.S. President Donald Trump has personally written to 17 top pharmaceutical CEOs — including Indian American Vasant Narasimhan, MD and CEO of Novartis — demanding an urgent action to bring down skyrocketing drug prices in the United States. The letters, signed by the President and disclosed at a White House briefing on Thursday (July 31, 2025), give companies time until September 29, 2025, to commit to offering Americans the same prices they charge in Europe and other developed nations. The announcement, delivered by White House press secretary Karoline Leavitte, marks a significant escalation in the administration's war on what it calls 'abusive drug pricing practices.' Trump ended conflicts including India-Pakistan, should get Nobel Peace Prize: White House Press Secretary 'For too long,' Ms. Leavitte told reporters, 'Americans have paid more than triple for the same life-saving medications compared to other countries. President Trump says this injustice ends now.' The letter addressed to Dr. Narasimhan and his peers includes four binding demands: extend global parity pricing to Medicaid, apply fair pricing to new drugs, redirect overseas profits to American patients, and enable direct consumer purchases at internationally benchmarked prices. Each letter was tailored but echoed the same urgent message: the days of global freeloading on American innovation are over. Trump and team 'frustrated' with India over trade talks, says U.S. Treasury Secretary 'This unacceptable burden on hardworking American families ends with my administration,' Mr. Trump wrote, warning companies that if they fail to comply, the White House will 'deploy every tool in our arsenal.' Among the many recipients of these letters is Novartis CEO Vasant Narasimhan, a U.S.-trained physician who has led the Swiss pharmaceutical giant since 2018. While Novartis is headquartered in Basel, Switzerland, it derives substantial revenue from U.S. patients and government programmes. Behind the policy is a human story. During the briefing, Ms. Leavitte read a letter from a mother in Ohio who struggles to afford insulin for her son, even while working two jobs. 'This is about people,' she said. 'Families are being forced to choose between rent and medicine.' In his letter, Mr. Trump said the unacceptable burden on hardworking American families ends with his administration. 'Most proposals the Trump administration has received to resolve this critical issue promised more of the same, shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' he said. 'Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations. Accordingly, I'm calling on Eli Lilly and Company and every manufacturer doing business in our great country to take the following actions within the next 60 days: extend the most favoured nation pricing to Medicaid; guarantee most favoured nation pricing for newly launched drugs; return increased revenues abroad to American patients and taxpayers; provide for direct purchasing at most favoured nation pricing,' Mr. Trump wrote. (This article is published in an arrangement with 5WH.)
Mint
2 hours ago
- Mint
Trump talks tough on drug prices but his demands have softened
President Donald Trump appears to be easing up on his push to force drugmakers to cut their prices for U.S. patients, even as he ramps up the rhetoric he is deploying against the companies. The president on Thursday afternoon posted letters to his Truth Social platform that the White House had sent to 17 large pharmaceutical and biotech companies, saying they each have until late September to cut certain U.S. prices, or else the administration will 'deploy every tool in our arsenal to protect American families." Drug stocks fell in response. The S&P 500 Pharmaceuticals industry group index was down 2.7% Thursday, while the S&P 500 was down 0.4%. Still, the new demands Trump made on Thursday appear to require far less from the companies than had been implied by an executive order on drug pricing the president signed two months ago. In May, the White House resurfaced a proposal from the first Trump administration that would peg prices paid for prescription medicines in the U.S. to the lowest prices paid in other wealthy countries, the so-called most-favored-nation price. An executive order signed May 12 ordered federal agencies to determine most-favored-nation prices for drugs. It laid out penalties if the companies didn't make 'significant progress" toward lowering U.S. pricing to those levels. The order suggested that the most-favored-nation prices would apply to all U.S. drugs, regardless of whether they were paid for by the federal government or private payers, and whether the drugs were new or had been on the market for years. The new letters posted Thursday make narrower demands. Trump told drugmakers they must lower the prices of drugs already on the market to most-favored-nation rates only for Medicaid, the health insurance program for low-income Americans paid for jointly by state governments and the federal government. Medicaid already pays a steeply discounted rate for drugs under pre-existing programs. For all other payers, including Medicare and commercial plans, Trump says the most-favored-nation rates should only apply to newly launched medicines. 'I think Trump is, in some ways, softening his tone on most favored nation," Raymond James healthcare policy analyst Chris Meekins told Barron's. 'Originally, he said the U.S. will get the best price that any other nation gets for all products. Now he's carving out specific categories." Meekins said that the new approach is potentially more realistic. 'Attempting to try to make sure the U.S. gets better prices on future products is something companies can work with the administration to try to do going forward," he said. Details about the plan remain scarce. The drug industry lobby group PhRMA, in a statement, criticized the effort. 'Importing foreign price controls would undermine American leadership, hurting patients and workers," said PhRMA senior vice president Alex Schriver in a statement. 'At a time when China is threatening to overtake the U.S. in biopharmaceutical leadership, we need to ensure America continues to be the most attractive place in the world to develop innovative medicines." Trump sent the letters to top executives at AbbVie, Bristol Myers Squibb, Novartis, Gilead Sciences, Pfizer, and other companies. In the letters to Pfizer and Regeneron, he crossed out the surnames of the companies' CEOs, Albert Bourla and Leonard Schleifer, and wrote in their first names by hand. Write to Josh Nathan-Kazis at
